{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/obesity/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"892bc984-b7ae-5830-91da-e570afd541ed","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 6f3c691d-9687-4a8f-965c-5215db5f756b --><h2>Changes</h2><!-- end field 6f3c691d-9687-4a8f-965c-5215db5f756b -->","summary":null,"htmlStringContent":"<!-- begin item 3c771af5-a8fb-4c8e-b372-f3a91b3f42e2 --><!-- begin field 18f6144b-adc4-46b2-abd3-53e7e17c057a --><p><strong>December 2017 </strong>— reviewed. A literature search was conducted in November 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. The recommendations in this CKS topic have been updated in line with the National Institute for Health and Care Excellence (NICE) guideline <em>Obesity: identification, assessment and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/obesity/references/\">NICE, 2014</a>]<em>, </em>which replaces section 1.2 in the NICE guideline on <em>Obesity Prevention</em><em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/obesity/references/\">NICE, 2006a</a>]. The topic has also been restructured.</p><!-- end field 18f6144b-adc4-46b2-abd3-53e7e17c057a --><!-- end item 3c771af5-a8fb-4c8e-b372-f3a91b3f42e2 -->","topic":{"id":"c301533a-3c5f-5238-aac1-4bf163fabdf2","topicId":"ce3a3429-b3d0-4c54-8025-abb6e33dff88","topicName":"Obesity","slug":"obesity","lastRevised":"Last revised in December 2017","chapters":[{"id":"dd66ad3d-4814-5adc-92fb-39e3b4d8f788","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0fa3d01a-4842-5ec2-b85f-638b92e3ef14","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"64d9ae78-8203-5176-bef3-411c488b93dc","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"892bc984-b7ae-5830-91da-e570afd541ed","slug":"changes","fullItemName":"Changes"},{"id":"322163e5-1cb7-5dc8-b9ca-874d4fdb1a44","slug":"update","fullItemName":"Update"}]},{"id":"ef9a094b-abce-5a97-bee5-98c4986de194","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4772dece-06ea-5147-bc24-b36aae1dd6a3","slug":"goals","fullItemName":"Goals"},{"id":"57961a43-ade1-5671-bb4f-44614134ded9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"91fec363-e9d2-57df-a40e-dbbfce99eb80","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6f66b98c-4b76-5bad-a30b-597d598b7ff1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"820d050d-9427-5bcb-b0b5-6f7e333a2056","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ef76ada9-ccbd-5dcc-80d5-10c669767ffb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"fef14215-12d6-5f3e-893f-df50af3914c7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8cbe6b8e-e49a-5e5a-a6a9-a8418bd1db6d","slug":"definition","fullItemName":"Definition"},{"id":"68511bf4-0ad9-5032-9404-0d9c659a09fd","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"ae570c8c-13b3-5f83-a6cd-20cbd1e99dfd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d3a07f9f-8796-50a6-9b7e-be818027fc9d","slug":"complications","fullItemName":"Complications"},{"id":"b543814e-2966-5638-8ec9-7767c793f4fb","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ab0c929a-0525-5cc1-86b6-65b4e5658543","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d7700030-6b9b-5b4d-ab70-25bd30339658","slug":"identification-classification","fullItemName":"Identification and classification"}]},{"id":"04af64f4-0f60-5070-aaa3-0bdd9e7dd6f2","fullItemName":"Management","slug":"management","subChapters":[{"id":"e4b24d9e-7f0e-59a8-a645-c066aea705e7","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"495b0383-35b9-5867-bb77-aaaa0d5fdf66","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9f3444a7-5139-58ee-9fdf-470378719d4c","slug":"orlistat","fullItemName":"Orlistat"}]},{"id":"e90e6f47-5738-5130-8d94-294893d8720d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a9337ec8-ca00-5ca7-a462-63a97314e80e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9e1d9ebc-ef23-5b61-bec5-4e83c2199fc4","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"da92e3a5-0e63-5c04-b64f-d5488b75e819","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1780d629-8ef2-59a3-872b-3935a6ed76ce","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"748e81ae-7a14-5115-91a0-58f82c43a92f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"542915ac-f7c9-5a27-a026-35779f6e1dc9","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"fb8b0b27-c7ac-5950-ac6c-7ae225054a3d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"64d9ae78-8203-5176-bef3-411c488b93dc","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"6f87414a-955b-57b9-a944-7d7667dd01ab","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 89ac79ba-7be6-447a-8e77-8cd39d4439a8 --><h3>Previous changes</h3><!-- end field 89ac79ba-7be6-447a-8e77-8cd39d4439a8 -->","summary":null,"htmlStringContent":"<!-- begin item 857ff9ea-4838-4d7b-8707-4925bc8ebbd3 --><!-- begin field d30306a1-0731-4bcd-bc12-daff3ea3e52b --><p><strong>November 2016</strong> — minor update. The 2016 NICE Quality standards on <em>Obesity: clinical assessment and management </em>have been added to this topic.</p><p><strong>June 2015</strong> — minor update. Based on an update to the Summary of Product Characteristics (SPC) for Calcichew D3<sup>® </sup>chewable tablets, the interaction of orlistat with fat-soluble vitamins has been clarified.</p><p><strong>June 2013</strong> — minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>September to October 2012</strong> — reviewed. A literature search was conducted in August 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of this topic. No major changes to recommendations have been made, but recommendations for starting drug treatment have been amended in line with the SPC for orlistat (Xenical<sup>®</sup>).</p><p><strong>March 2011</strong> — topic structure revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made.</p><p><strong>February 2010</strong> — minor update. Advice on interactions between orlistat and levothyroxine and antiepileptic drugs has been added to the <em>Prescribing Information</em> section. Issued in February 2010.</p><p><strong>January 2010</strong> — updated. On 21 January 2010, the European Medicines Agency (EMEA)'s Committee for Medicinal Products for Human Use (CHMP) recommended the suspension of the marketing authorisation for sibutramine (Reductil<sup>®</sup>) because the benefits no longer outweigh the risks. This CKS topic has been updated to reflect the EMEA's decision. Recommendations regarding when to consider prescribing sibutramine as well as its prescribing information and prescriptions have been removed. Issued in January 2010.</p><p><strong>October 2008</strong> — updated. On 23 October 2008, the EMEA's CMHP recommended the suspension of the marketing authorisation for rimonabant (Acomplia<sup>®</sup>) because the benefits no longer outweigh the risks. This CKS topic has been updated to reflect the EMEA's decision. Recommendations regarding when to consider prescribing rimonabant as well as its prescribing information and prescriptions have been removed. Issued in November 2008.</p><p><strong>July 2008</strong> — minor update to incorporate the recommendation from NICE that rimonabant may now be prescribed as an alternative to orlistat or sibutramine. A scenario on prescribing rimonabant<em> </em>has been added.</p><p><strong>May 2008</strong> — minor update to text to reflect updated advice from the Medicines and Healthcare products Regulatory Agency (MHRA) regarding rimonabant. Issued June 2008.</p><p><strong>June to September 2007</strong> — converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There have been no major changes to the recommendations. This update incorporates recommendations from the NICE guideline <em>Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children</em>.</p><p><strong>July 2006</strong> — minor update. Information regarding orlistat and reduced efficacy of oral contraceptives has been included.</p><p><strong>July–September 2005</strong> — reviewed. Validated in December 2005 and issued in February 2006.</p><p><strong>March 2002</strong> — reviewed. Validated in June 2002 and issued in July 2002.</p><p><strong>June 2001</strong> — updated to incorporate recommendations in the NICE technology appraisal <em>Guidance on the use of orlistat for the treatment of obesity in adults</em> and <em>Statistics on Obesity</em> published by the National Audit Office. Validated in July 2001 and issued in October 2001.</p><!-- end field d30306a1-0731-4bcd-bc12-daff3ea3e52b --><!-- end item 857ff9ea-4838-4d7b-8707-4925bc8ebbd3 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}